Next generation Tau PET-Tracer, 18F-PI-2620, offers opportunities to diagnose and monitor tauopathies, including AD and PSP
New data further support 18F-PI-2620’s potential as a new PET Tracer for progressive supranuclear palsy (PSP) detection
LAUSANNE,
The progression of Tau pathology has been shown to be closely associated with neuronal loss, neurodegeneration, and cognitive decline in Alzheimer’s disease and other tauopathies.
LMI is developing 18F-PI-2620 for detection of the two isoforms of Tau aggregates in AD and Non-AD Tauopathies that are characterized by different Tau isoforms (3R and 4R) 18F-PI-2620 has potential applications as a diagnostic agent to confirm and monitor disease progression as well as responses to treatment. Due to its excellent signal-to-background ratio, 18F-PI-2620 has the potential to detect Tau deposits in early stages of AD. To date, no Tau tracer has been approved by the
“We are particularly pleased that 18F-PI-2620 depicts the characteristic Tau-deposition pattern in patients with Progressive Supranuclear Palsy (PSP)” said Prof.
The following presentations on 18F-PI-2620 will be provided at the AD/PD conference by scientists from Life Molecular Imaging and its collaboration partners:
Determination of the optimal scanning time for the assessment of Tau deposition in Alzheimer’s Disease using PI-2620 PET
Date:
Location: Auditorium III+IV
Presenter: Oral presentation by A. Stephens
18F-PI-2620 Tau-PET in progressive supranuclear palsy – a multi-center evaluation
Date:
Location: Auditorium VI+VII
Presenter: Oral presentation by T. Van Eimeren
Evaluation of Tau deposition in amyloid positive MCI or mild-AD dementia subjects from the elenbecestat MissionAD program using 18F-PI-2620 PET
Date:
Location: Exhibition
Presenter: Poster presentation by A. Stephens
Under the 2014 agreement LMI has exclusive global rights for clinical development, manufacturing and commercialization of Tau-PET tracers resulting from the joint discovery and development collaboration. In exchange,
About
For further information, please contact:
US Investors Lisa Sher AC Immune Investor Relations Phone: +1 970 987 2654 E-mail: lisa.sher@acimmune.com |
US Media Katie Gallagher LaVoieHealthScience Phone: +1 617 792 3937 E-mail: kgallagher@lavoiehealthscience.com |
European Investors & Media Chris Maggos LifeSci Advisors Phone: +41 79 367 6254 E-mail: chris@lifesciadvisors.com |
Forward looking statements
This press release contains statements that constitute “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements are statements other than historical fact and may include statements that address future operating, financial or business performance or AC Immune’s strategies or expectations. In some cases, you can identify these statements by forward-looking words such as “may,” “might,” “will,” “should,” “expects,” “plans,” “anticipates,” “believes,” “estimates,” “predicts,” “projects,” “potential,” “outlook” or “continue,” and other comparable terminology. Forward-looking statements are based on management’s current expectations and beliefs and involve significant risks and uncertainties that could cause actual results, developments and business decisions to differ materially from those contemplated by these statements. These risks and uncertainties include those described under the captions “Item 3. Key Information – Risk Factors” and “Item 5. Operating and Financial Review and Prospects” in AC Immune’s Annual Report on Form 20-F and other filings with the
Source: AC Immune SA